In addition, MD-265 is a potent PROTAC MDM2 degrader that selectively depletes MDM2, activates p53 in wild-type p53 cancer cells, induces sustained tumor regression in leukemia models with minimal toxicity, and exhibits a favorable pharmacokinetic profile, making it a strong candidate for advanced preclinical cancer therapy development (Aguilar et al., 2024). This evidence concerns the gene MDM2 and neoplasm.